ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/clear-cell-renal/adjuvant-neoadjuvant
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Prostate and Urogenital / Clear cell renal - Adjuvant/Neoadjuvant
3
trial(s) found.
NCT05024318
Curative
Phase 2
Recruiting
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes (
NAPSTER
)
anti-PD-1 monoclonal antibody
radiotherapy
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06307431
Curative
Phase 2
Active not recruiting
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (
INTerpath-004
).
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05239728
Curative
Phase 3
Active not recruiting
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-
6482-022
)
HIF2a inhibitor
anti-PD-1 monoclonal antibody
placebo
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Active not recruiting (2)
Recruiting (1)
Recruitment Country and State
QLD (3)
VIC (2)
NSW (2)
WA (2)
NZ (1)
SA (1)
Phase
Phase 2 (2)
Phase 3 (1)
Trial Type
Curative (3)
Cancer Therapy Class
PD-1
100%
PD-1/PD-L1
100%
HIF2a
33%
Facility
2109 - North Ryde - Macquarie University Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Clear cell renal cell carcinoma
Kidney cancer
Solid tumour
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy